NCT05677750 (HEMATOCOVID) is a clinical trial in Hematological Condition With COVID19, sponsored by Assiut University.

Who is sponsoring NCT05677750?

NCT05677750 is sponsored by Assiut University.

What condition does NCT05677750 study?

NCT05677750 studies Hematological Condition With COVID19.

Is NCT05677750 still recruiting?

NCT05677750 is currently completed. Last updated 10 January 2023.

Last reviewed 2023-01-10 · How we verify

NCT05677750: HEMATOCOVID

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hematological Disorders Associated With COVID-19 Infection

Completed Last updated 10 January 2023

What this trial tests

trial in Hematological Condition With COVID19 in 40 participants. Completed in 1 October 2022.

Timeline

1 August 2021

Primary endpoint
30 July 2022

1 October 2022

Quick facts

Lead sponsor	Assiut University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	40
Start date	1 August 2021
Primary completion	30 July 2022
Estimated completion	1 October 2022
Sites	1 location across Egypt

Conditions studied

Hematological Condition With COVID19 — all drugs for Hematological Condition With COVID19 →

Sponsor

Assiut University

Who can join

Adults 1 to 18, any sex, with Hematological Condition With COVID19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The emergence of the Coronavirus Disease -19 (COVID-19) pandemic, has had a tremendous global impact, resulting in substantial morbidity and mortality worldwide. Although involvement of the lower respiratory track accounts for most of the morbidity and mortality seen, the virus involves several organ systems and the syndrome exhibits clinical diversity with a wide range of symptoms and manifestations. Aim of this study is to evaluate if there is a casual relationship between the development of aplastic anemias\& other immune cytopenias, and recent COVID-19 infection.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Assiut University trials

Trials by the same sponsor.

NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05677750 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assiut University
Last refreshed: 10 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05677750.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing